New strategies in Barrett's esophagus: Integrating clonal evolutionary theory with clinical management

Brian J. Reid, Rumen Kostadinov, Carlo C. Maley

Research output: Contribution to journalArticle

Abstract

Barrett's esophagus is a condition in which the normal stratified squamous epithelium of the distal esophagus is replaced by intestinal metaplasia. For more than three decades, the prevailing clinical paradigm has been that Barrett's esophagus is a complication of symptomatic reflux disease that predisposes to esophageal adenocarcinoma. However, no clinical strategy for cancer prevention or early detection based on this paradigm has been proven to reduce esophageal adenocarcinoma mortality in a randomized clinical trial in part because only about 5% to 10% of individuals with Barrett's esophagus develop esophageal adenocarcinoma. Recent research indicates that Barrett's metaplasia is an adaptation for mucosal defense in response to chronic reflux in most individuals. The risk of progressing to esophageal adenocarcinoma is determined by development of genomic instability and dynamic clonal evolution in the distal esophagus modulated by host and environmental risk and protective factors, including inherited genotype. The challenge for investigators of Barrett's esophagus lies in integrating knowledge about genomic instability and clonal evolution into clinical management to increase the lifespan and quality of life of individuals with this condition.

Original languageEnglish (US)
Pages (from-to)3512-3519
Number of pages8
JournalClinical Cancer Research
Volume17
Issue number11
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Barrett Esophagus
Adenocarcinoma
Clonal Evolution
Genomic Instability
Esophagus
Metaplasia
Epithelium
Randomized Controlled Trials
Genotype
Quality of Life
Research Personnel
Mortality
Research
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New strategies in Barrett's esophagus : Integrating clonal evolutionary theory with clinical management. / Reid, Brian J.; Kostadinov, Rumen; Maley, Carlo C.

In: Clinical Cancer Research, Vol. 17, No. 11, 01.06.2011, p. 3512-3519.

Research output: Contribution to journalArticle

@article{8a152dbda7f2458f93c8cec05aa9a6a4,
title = "New strategies in Barrett's esophagus: Integrating clonal evolutionary theory with clinical management",
abstract = "Barrett's esophagus is a condition in which the normal stratified squamous epithelium of the distal esophagus is replaced by intestinal metaplasia. For more than three decades, the prevailing clinical paradigm has been that Barrett's esophagus is a complication of symptomatic reflux disease that predisposes to esophageal adenocarcinoma. However, no clinical strategy for cancer prevention or early detection based on this paradigm has been proven to reduce esophageal adenocarcinoma mortality in a randomized clinical trial in part because only about 5{\%} to 10{\%} of individuals with Barrett's esophagus develop esophageal adenocarcinoma. Recent research indicates that Barrett's metaplasia is an adaptation for mucosal defense in response to chronic reflux in most individuals. The risk of progressing to esophageal adenocarcinoma is determined by development of genomic instability and dynamic clonal evolution in the distal esophagus modulated by host and environmental risk and protective factors, including inherited genotype. The challenge for investigators of Barrett's esophagus lies in integrating knowledge about genomic instability and clonal evolution into clinical management to increase the lifespan and quality of life of individuals with this condition.",
author = "Reid, {Brian J.} and Rumen Kostadinov and Maley, {Carlo C.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-09-2358",
language = "English (US)",
volume = "17",
pages = "3512--3519",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - New strategies in Barrett's esophagus

T2 - Integrating clonal evolutionary theory with clinical management

AU - Reid, Brian J.

AU - Kostadinov, Rumen

AU - Maley, Carlo C.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Barrett's esophagus is a condition in which the normal stratified squamous epithelium of the distal esophagus is replaced by intestinal metaplasia. For more than three decades, the prevailing clinical paradigm has been that Barrett's esophagus is a complication of symptomatic reflux disease that predisposes to esophageal adenocarcinoma. However, no clinical strategy for cancer prevention or early detection based on this paradigm has been proven to reduce esophageal adenocarcinoma mortality in a randomized clinical trial in part because only about 5% to 10% of individuals with Barrett's esophagus develop esophageal adenocarcinoma. Recent research indicates that Barrett's metaplasia is an adaptation for mucosal defense in response to chronic reflux in most individuals. The risk of progressing to esophageal adenocarcinoma is determined by development of genomic instability and dynamic clonal evolution in the distal esophagus modulated by host and environmental risk and protective factors, including inherited genotype. The challenge for investigators of Barrett's esophagus lies in integrating knowledge about genomic instability and clonal evolution into clinical management to increase the lifespan and quality of life of individuals with this condition.

AB - Barrett's esophagus is a condition in which the normal stratified squamous epithelium of the distal esophagus is replaced by intestinal metaplasia. For more than three decades, the prevailing clinical paradigm has been that Barrett's esophagus is a complication of symptomatic reflux disease that predisposes to esophageal adenocarcinoma. However, no clinical strategy for cancer prevention or early detection based on this paradigm has been proven to reduce esophageal adenocarcinoma mortality in a randomized clinical trial in part because only about 5% to 10% of individuals with Barrett's esophagus develop esophageal adenocarcinoma. Recent research indicates that Barrett's metaplasia is an adaptation for mucosal defense in response to chronic reflux in most individuals. The risk of progressing to esophageal adenocarcinoma is determined by development of genomic instability and dynamic clonal evolution in the distal esophagus modulated by host and environmental risk and protective factors, including inherited genotype. The challenge for investigators of Barrett's esophagus lies in integrating knowledge about genomic instability and clonal evolution into clinical management to increase the lifespan and quality of life of individuals with this condition.

UR - http://www.scopus.com/inward/record.url?scp=79957881949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957881949&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-2358

DO - 10.1158/1078-0432.CCR-09-2358

M3 - Article

C2 - 21498395

AN - SCOPUS:79957881949

VL - 17

SP - 3512

EP - 3519

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -